세포 및 유전자 치료 제3자 물류 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 온도 범위별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Cell & Gene Therapy Third-Party Logistics Market Growth & Trends:

The global cell and gene therapy third-party logistics market is expected to reach USD 20.04 billion by 2030, expanding at a CAGR of 11.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is mainly due to rising demand for cell and gene therapies, which require precise handling, strict temperature controls, and seamless coordination between manufacturers, hospitals, and treatment centers. CGTs are patient-specific, which signifies that a single patient's cells must be collected, transported, modified, and reinfused within tight timelines. Any failure in logistics can result in the loss of an expensive, potentially life-saving therapy. The personalized nature of CGTs has increased the need for advanced cold chain logistics, with cryogenic storage and ultra-low temperature transportation becoming standard requirements.

In addition, the growing pipeline of CGT clinical trials and commercial approvals encourages logistics providers to scale their capabilities, ensuring that the increasing volume of therapies reaches patients without compromising quality. This shift is compelling biopharmaceutical companies to seek specialized 3PL partners that can handle the complexities of CGT supply chains, ensuring compliance with strict regulatory requirements while optimizing distribution efficiency. Moreover, the growing regulatory support is also one of the factors contributing to market growth. The U.S. FDA, EMA, and other global regulatory bodies impose stringent guidelines on the transportation and storage of CGTs to maintain their potency and safety. Regulatory compliance requires logistics providers to implement Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP) standards, which govern every aspect of supply chain management, from packaging to real-time tracking. Failure to comply can result in rejected shipments, financial losses, and treatment delays for patients.

Furthermore, growing initiatives by the market players, such as partnerships and collaborations, service expansion, product launches, and increasing pipeline products, contribute to market growth. For instance, in March 2025, DHL acquired CryoPDP, a specialist in temperature-controlled logistics for life sciences. The acquisition aims to strengthen the infrastructure for handling advanced therapies. CryoPDP's expertise in ultra-cold storage and real-time monitoring solutions aligns with DHL's strategy, providing end-to-end solutions for biopharma companies.

Cell And Gene Therapy Third-Party Logistics Market Report Highlights:

• Based on type, the clinical segment dominated the market due to the increasing number of research and development activities by the market players coupled with the growing number of cell and gene therapies product pipelines.
• Based on the product, cell therapies dominated the market in 2024 due to increasing regulatory approvals and expanding commercialization efforts. The success of CAR-T cell therapies for cancer treatment played a crucial role in this growth, with companies like Novartis, Gilead Sciences, and Bristol Myers Squibb driving widespread adoption.
• Based on temperature range, ambient storage held the largest market share in 2024due to the increasing demand for gene therapies, biologics, and regenerative medicine products that do not require ultra-low or cryogenic temperatures.
• Based on the therapeutic area, the oncology segment dominated the market in 2024due to the rapid adoption of advanced therapies for treating various cancers, particularly hematologic and solid tumors.
• Based on end use, biopharmaceutical companies held the largest market share in 2024due to their high reliance on temperature-controlled storage and transportation for biologics and specialty drugs.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Technology Landscape
• 3.5. Pricing Model Analysis
• 3.6. Industry Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Cell & Gene Therapy Third-Party Logistics Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Cell & Gene Therapy Third-Party Logistics Market; Type Movement Analysis
• 4.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Clinical
  • 4.4.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Commercial
  • 4.5.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cell & Gene Therapy Third-Party Logistics Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Cell & Gene Therapy Third-Party Logistics Market; Product Movement Analysis
• 5.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 5.4. Cell Therapies
  • 5.4.1. Cell therapies market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Gene Therapies
  • 5.5.1. Gene therapies market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cell & Gene Therapy Third-Party Logistics Market: Temperature Range Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Cell & Gene Therapy Third-Party Logistics Market; Temperature Range Movement Analysis
• 6.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Temperature Range, 2018 to 2030 (USD Million)
• 6.4. Ambient Storage
  • 6.4.1. Ambient storage market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Refrigerated Storage
  • 6.5.1. Refrigerated storage market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Ultra-Low Temperature Storage
  • 6.6.1. Ultra-Low temperature storage market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Cryogenic Storage
  • 6.7.1. Cryogenic storage market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cell & Gene Therapy Third-Party Logistics Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Cell & Gene Therapy Third-Party Logistics Market; Therapeutic Area Movement Analysis
• 7.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Neurology
  • 7.5.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Cardiovascular Diseases
  • 7.6.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Ophthalmology
  • 7.7.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Infectious Diseases
  • 7.8.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Cell & Gene Therapy Third-Party Logistics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Cell & Gene Therapy Third-Party Logistics Market; End Use Movement Analysis
• 8.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Biopharmaceutical Companies
  • 8.4.1. Biopharmaceutical Companies market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. CDMOs/CMOs
  • 8.5.1. CDMOs/CMOs market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 9.3. North America
  • 9.3.1. North America cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Competitive scenario
    • 9.3.2.3. Regulatory framework
    • 9.3.2.4. U.S. cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Competitive scenario
    • 9.3.3.3. Regulatory framework
    • 9.3.3.4. Canada cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Competitive scenario
    • 9.3.4.3. Regulatory framework
    • 9.3.4.4. Mexico cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. Germany cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. UK cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. France cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Competitive scenario
    • 9.4.5.3. Regulatory framework
    • 9.4.5.4. Italy cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Competitive scenario
    • 9.4.6.3. Regulatory framework
    • 9.4.6.4. Spain cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Competitive scenario
    • 9.4.7.3. Regulatory framework
    • 9.4.7.4. Denmark cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Competitive scenario
    • 9.4.8.3. Regulatory framework
    • 9.4.8.4. Sweden cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Competitive scenario
    • 9.4.9.3. Regulatory framework
    • 9.4.9.4. Norway cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. Japan cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. China cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. India cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. South Korea cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Australia cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Thailand cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Brazil cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. Argentina cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. South Africa cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Saudi Arabia cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Competitive scenario
    • 9.7.4.3. Regulatory framework
    • 9.7.4.4. UAE cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Competitive scenario
    • 9.7.5.3. Regulatory framework
    • 9.7.5.4. Kuwait cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Company Market Share/Assessment Analysis, 2024
• 10.3. Company Profiles
  • 10.3.1. Cencora Corporation
    • 10.3.1.1. Company overview
    • 10.3.1.2. Financial performance
    • 10.3.1.3. Service benchmarking
    • 10.3.1.4. Strategic initiatives
  • 10.3.2. Cardinal Health
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Service benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. McKesson Corporation
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Service benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. EVERSANA
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Service benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Knipper Health
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Service benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Arvato SE
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Service benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. DHL
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Service benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. FedEx
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Service benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Kuehne+Nagel
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Service benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. United Parcel Service of America, Inc.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Service benchmarking
    • 10.3.10.4. Strategic initiatives